These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28811131)

  • 1. Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts.
    Visser SAG; Bueters TJH
    Eur J Pharm Sci; 2017 Nov; 109S():S72-S77. PubMed ID: 28811131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems pharmacology - Towards the modeling of network interactions.
    Danhof M
    Eur J Pharm Sci; 2016 Oct; 94():4-14. PubMed ID: 27131606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "White Knight" role for DMPK researchers in pharmaceutical discovery: maximization of biomarker and translational M&S activities.
    Teramura T
    Drug Metab Pharmacokinet; 2012; 27(4):365-7. PubMed ID: 23268314
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.
    Danhof M; Alvan G; Dahl SG; Kuhlmann J; Paintaud G
    Pharm Res; 2005 Sep; 22(9):1432-7. PubMed ID: 16132354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery.
    Zhang R; Wong K
    Expert Opin Drug Discov; 2017 Jan; 12(1):17-37. PubMed ID: 27784173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometry-based biomarkers in drug development.
    Miller RA; Spellman DS
    Adv Exp Med Biol; 2014; 806():341-59. PubMed ID: 24952191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gPKPDSim: a SimBiology
    Hosseini I; Gajjala A; Bumbaca Yadav D; Sukumaran S; Ramanujan S; Paxson R; Gadkar K
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):259-275. PubMed ID: 29302838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in Pharmaceutical Research.
    Zhao X; Modur V; Carayannopoulos LN; Laterza OF
    Clin Chem; 2015 Nov; 61(11):1343-53. PubMed ID: 26408531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers.
    Day M; Rutkowski JL; Feuerstein GZ
    Adv Exp Med Biol; 2009; 655():1-12. PubMed ID: 20047030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding and applying pharmacometric modelling and simulation in clinical practice and research.
    Standing JF
    Br J Clin Pharmacol; 2017 Feb; 83(2):247-254. PubMed ID: 27567102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for In Vivo Assessment of Transporter Function.
    Müller F; Sharma A; König J; Fromm MF
    Pharmacol Rev; 2018 Apr; 70(2):246-277. PubMed ID: 29487084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.